Bioequivalence of Oral Products and the Biopharmaceutics Classification System: Science, Regulation, and Public Policy

被引：35
|
作者：
Amidon, K. S. [2 ]
Langguth, P. [3 ]
Lennernas, H. [4 ]
Yu, L. [5 ]
Amidon, G. L. [1 ]
机构：
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Iowa State Univ, Dept World Languages & Cultures, Ames, IA USA
[3] Johannes Gutenberg Univ Mainz, Dept Biopharm & Pharmaceut Technol, Mainz, Germany
[4] Uppsala Univ, Dept Pharm, Uppsala, Sweden
[5] US FDA, Off Gener Drugs, Rockville, MD 20857 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 90卷 / 03期
关键词：
INTESTINAL PERMEABILITY; UNITED-STATES; DRUG; CACO-2; BCS; FDA;
D O I：
10.1038/clpt.2011.109
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The demonstration of bioequivalence (BE) is an essential requirement for ensuring that patients receive a product that performs as indicated by the label. The BE standard for a particular product is set by its innovator, and this standard must subsequently be matched by generic drug products. The Biopharmaceutics Classification System (BCS) sets a scientific basis for an improved BE standard for immediate-release solid oral dosage forms. In this paper, we discuss BE and the BCS, as well as the issues that are currently relevant to BE as a pharmaceutical product standard.
引用
收藏
页码：467 / 470
页数：4
相关论文
共 50 条
  • [1] Summary workshop report: Bioequivalence, biopharmaceutics classification system, and beyond
    Polli, James E.
    Abrahamsson, Bertil S. I.
    Yu, Lawrence X.
    Amidon, Gordon L.
    Baldoni, John M.
    Cook, Jack A.
    Fackler, Paul
    Hartauer, Kerry
    Johnston, Gordon
    Krill, Steve L.
    Lipper, Robert A.
    Malick, Waseem A.
    Shah, Vinod P.
    Sun, Duxin
    Winkle, Helen N.
    Wu, Yunhui
    Zhang, Hua
    AAPS JOURNAL, 2008, 10 (02): : 373 - 379
  • [2] Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond
    James E. Polli
    Bertil S. I. Abrahamsson
    Lawrence X. Yu
    Gordon L. Amidon
    John M. Baldoni
    Jack A. Cook
    Paul Fackler
    Kerry Hartauer
    Gordon Johnston
    Steve L. Krill
    Robert A. Lipper
    Waseem A. Malick
    Vinod P. Shah
    Duxin Sun
    Helen N. Winkle
    Yunhui Wu
    Hua Zhang
    The AAPS Journal, 2008, 10 : 373 - 379
  • [3] A Comparative Analysis of Biopharmaceutics Classification System and Biopharmaceutics Drug Disposition Classification System: A Cross-Sectional Survey with 500 Bioequivalence Studies
    Cristofoletti, Rodrigo
    Chiann, Chang
    Dressman, Jennifer B.
    Storpirtis, Silvia
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (09) : 3136 - 3144
  • [4] Oral drug absorption and the biopharmaceutics classification system
    Lennernas, H.
    Abrahamsson, B.
    Persson, E. M.
    Knutson, L.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2007, 17 (04) : 237 - 244
  • [5] Applying the Biopharmaceutics Classification System to veterinary pharmaceutical products Part I: Biopharmaceutics and formulation considerations
    Martinez, M
    Augsburger, L
    Johnston, T
    Jones, WW
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (06) : 805 - 824
  • [6] Basic Science and Public Policy: Informed Regulation for Nicotine and Tobacco Products
    Fowler, Christie D.
    Gipson, Cassandra D.
    Kleykamp, Bethea A.
    Rupprecht, Laura E.
    Harrell, Paul T.
    Rees, Vaughan W.
    Gould, Thomas J.
    Oliver, Jason
    Bagdas, Deniz
    Damaj, M. Imad
    Schmidt, Heath D.
    Duncan, Alexander
    De Biasi, Mariella
    NICOTINE & TOBACCO RESEARCH, 2018, 20 (07) : 789 - 799
  • [7] Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs
    Ren, Ping
    Chan, Theresa
    Yang, Wen-Cheng
    Frost, Mitchell
    Wang, Yan
    Luke, Markham
    Kim, Myong-Jin
    Lionberger, Robert
    Zhang, Yi
    PHARMACEUTICS, 2023, 15 (09)
  • [8] Very Rapid Dissolution Is Not Needed to Guarantee Bioequivalence for Biopharmaceutics Classification System (BCS) I Drugs
    Kortejarvi, H.
    Shawahna, R.
    Koski, A.
    Malkki, J.
    Ojala, K.
    Yliperttula, M.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (02) : 621 - 625
  • [9] Modern bioavailability, bioequivalence and biopharmaceutics classification system.: New scientific approaches to international regulatory standards
    Löbenberg, R
    Amidon, GL
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) : 3 - 12
  • [10] A Perspective for Biowaivers of Human Bioequivalence Studies on the Basis of the Combination of the Ratio of AUC to the Dose and the Biopharmaceutics Classification System
    Sakuma, Shinji
    Tachiki, Hidehisa
    Uchiyama, Hitoshi
    Fukui, Yasunobu
    Takeuchi, Naohiro
    Kumamoto, Kazuo
    Satoh, Tomonori
    Yamamoto, Yoshinobu
    Ishii, Emi
    Sakai, Yoshiyuki
    Takeuchi, Susumu
    Sugita, Masaru
    Yamashita, Shinji
    MOLECULAR PHARMACEUTICS, 2011, 8 (04) : 1113 - 1119
12345